People who only had one job and couldn’t get it right. Fans walk out of Wizard of Oz Christmas show: 'It was atrocious' Florida’s 'forgotten' coastline offers quaint towns and fresh seafood without ...

In a letter dated December 9, and made public on December 10 according to Reuters, dozens of state and territorial attorneys general from all over the U.S. warned Big Tech that it needs to do a better ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

The company said Friday Deep most recently served as executive VP of global operations at General Dynamics, a role he took on in June. His previous roles at the company include EVP of combat systems ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

It was delightful to read a recent investigative report detailing Attorney General Aaron Ford’s busy travel schedule. Having worked alongside leadership figures in both public and private business ...